Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA [Yahoo! Finance]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Yahoo! Finance
autoleucel ( miv-cel met the primary endpoint at week 16 with a median 46% improvement in T25FW (81% of patients =20% improvement), sustained through 24 weeks in evaluable patients, and was well tolerated with no high-grade CRS/ICANS. In the KYSA-6 cohort for generalized myasthenia gravis, miv-cel produced rapid, durable responses—100% of patients were clinically meaningful responders on MG-ADL and QMG through 24 weeks—accompanied by deep B-cell depletion and preservation of humoral responses to common vaccines. Kyverna is prioritizing an SPS BLA as it pursues what it calls a potential first approval for a CAR-T in autoimmunity , targeting an initial US addressable population of ~2,000–2,500 patients with an early rollout at roughly 10 treatment centers. Interested in Kyverna Therapeutics, Inc.? Here are five stocks we like better. Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics (KYTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis [Seeking Alpha]Seeking Alpha
- Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingGlobeNewswire
- Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample [Seeking Alpha]Seeking Alpha
- Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 WeeksGlobeNewswire
KYTX
Earnings
- 3/26/26 - In-Line
KYTX
Analyst Actions
- 4/23/26 - HC Wainwright
KYTX
Sec Filings
- 4/22/26 - Form 8-K
- 4/22/26 - Form 8-K
- 4/20/26 - Form 8-K
- KYTX's page on the SEC website